2026-01-15 - Analysis Report
**Company Overview:** Thermo Fisher Scientific Inc is a leader in life sciences and laboratory equipment.

### Comparison of Return Rates

| Metric | TMO | VOO |
|--------|-----|-----|
| Cumulative Return (%) | 38.73% | 93.94% |
| Rate Difference | -55.20 (points) | - |
| Relative Divergence | 11.70% | - |

The return rate of TMO is lower compared to VOO, with a divergence of -55.20 points.

### Alpha, Beta Analysis

| Period | CAGR | MDD | Alpha | Beta | Cap(B) |
|---------|------|------|-------|------|--------|
| 2016-2018 | 21.0% | 17.1% | 17.0% | 1.1 | 86.0B |
| 2017-2019 | 46.0% | 17.1% | 29.0% | 1.1 | 124.8B |
| 2018-2020 | 22.0% | 17.1% | 1.0% | 0.8 | 178.9B |
| 2019-2021 | 77.0% | 15.0% | 34.0% | 0.8 | 256.3B |
| 2020-2022 | 8.0% | 25.4% | 10.0% | 0.8 | 211.5B |
| 2021-2023 | -30.0% | 28.6% | -31.0% | 0.9 | 203.9B |
| 2022-2024 | -37.0% | 24.4% | -57.0% | 0.9 | 199.8B |
| 2023-2025 | -17.0% | 27.2% | -79.0% | 0.8 | 222.6B |

There are significant variations in CAGR, MDD, Alpha, and Beta across different periods, indicating market volatility and changing trends.

### Recent Stock Price Fluctuations

| Metric | Value |
|--------|-------|
| Close | $607.08 |
| Last-Market | $620.725 |
| 5-day SMA | $613.01 |
| 20-day SMA | $589.59 |
| 60-day SMA | $578.15 |

Recent stock price fluctuations show a sharp rebound, with the closing price higher than the last-market price. 

### RSI, PPO Index and Delta_Previous_Relative_Divergence

| Metric | Value |
|--------|-------|
| RSI | 66.30 |
| PPO | 0.40 |
| Magnetic Risk Indicator (MRI) | 0.70 |
| Recent Relative Divergence Change | -2.80 (worsening) |
| 7-Day Rank Change | 0 (flat) |
| 7-Day Dynamic Expected Return Change | 0 (flat) |
| Expected Return | -54.10% |

Market risk is medium, and the expected return is negative, indicating a sharp decline in the stock price.

### Recent News & Significant Events

* [2026-01-14] Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now? - TradingView
* [2026-01-14] Will Thermo Fisher’s AI Push and Leadership Shuffle Redefine TMO’s Innovation and Execution Narrative? - simplywall.st
* [2025-12-31] Here’s What Lifted Thermo Fisher Scientific (TMO) in Q3 - Yahoo Finance
* [2026-01-12] Thermo Fisher (TMO) stock slips after COO exit disclosed; AI lab deals put focus on JPM talk - TechStock²
* [2026-01-12] How Thermo Fisher and NVIDIA want to turn routine labs into AI powerhouses - Stock Titan
* [2026-01-13] Lobbying Update: $30,000 of THERMO FISHER SCIENTIFIC INC lobbying was just disclosed - Quiver Quantitative

### Analyst Opinions

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.54 (~Buy)
- Opinions: 23
- Target Price (avg/high/low): 651.52 / 750.00 / 575.00

### Recent Earnings Analysis

| Date | EPS | Revenue |
|------|-----|----------|
| 2025-10-31 | 4.28 | 11.12 B$ |
| 2025-08-01 | 4.28 | 10.86 B$ |
| 2025-05-02 | 3.99 | 10.36 B$ |
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2025-10-31 | 4.26 | 10.60 B$ |

EPS is consistent, while revenue sees fluctuations across quarters.

### Financial Information

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.12B | 41.21% |
| 2025-06-30 | $10.85B | 40.61% |
| 2025-03-31 | $10.36B | 40.86% |
| 2024-12-31 | $11.39B | 42.32% |
| 2024-09-30 | $10.60B | 40.84% |

**Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.02B | 3.17% |
| 2025-06-30 | $50.51B | 3.20% |
| 2025-03-31 | $49.39B | 3.05% |
| 2024-12-31 | $49.59B | 3.69% |
| 2024-09-30 | $48.99B | 3.33% |

Equity and ROE see fluctuations across quarters, indicating changes in the company's financial position and profitability.

### Comprehensive Analysis (Summary of previous items)

* TMO return rate is lower than VOO, with a divergence of -55.20 points.
* Market risk is high.
* The company's financial position and profitability see fluctuations across quarters.
* EPS is consistent, while revenue sees fluctuations across quarters.
* The current market situation does not favor long-term investment for TMO.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.